TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In the SIMPLIFIED trial, high-dose vitamin D3 did not significantly improve overall survival or several other health outcomes for adults receiving dialysis. Researchers reported possible signals in male and non-white participants, but said these subgroup findings are exploratory and need further study.
High-dose vitamin D3 did not significantly improve overall survival among adults receiving dialysis for end-stage kidney disease in the SIMPLIFIED trial, according to results presented October 26 at the American Society of Nephrology Kidney Week meeting. The study compared supplementation with standard care and found no significant difference in its primary outcome over a median 7.5 years of follow-up.
The pragmatic U.K. trial randomized 3,866 adults receiving dialysis at 55 renal units to take 60,000 international units of cholecalciferol, or vitamin D3, every two weeks, or to receive standard care without the study supplement. Overall survival was similar between the groups: the reported conditional hazard ratio was 0.95 (95% confidence interval 0.86-1.04; P=0.26). The result did not meet the study’s threshold for a significant difference.
There were 1,817 deaths during the trial. Researchers also reported no significant differences in secondary outcomes including fatal and nonfatal cardiovascular events, infections, fractures and malignancy. Sensitivity analyses that accounted for kidney transplantation, COVID-19 infection and stopping treatment did not change the primary result. At least one hospital admission occurred in 69% of the vitamin D group and 70% of the standard-care group.
The treatment raised vitamin D levels in an early sample: after four months, median 25-hydroxyvitamin D was 141 nmol/L among supplemented participants and 36.5 nmol/L among controls, based on the first 206 participants assessed. The researchers described high-dose cholecalciferol as safe and well tolerated in the trial. That increase in a blood measure did not translate into a demonstrated survival benefit.
Routine Vitamin D Use in Dialysis
The findings address a practical question for people receiving dialysis: whether a high-dose vitamin D supplement can improve survival or prevent major health events in a group with substantial long-term health risks. Trial lead investigator Rona Smith of the University of Cambridge said that about half of people who begin dialysis are not alive five years later, and that cardiovascular disease accounts for most deaths in this population.
Low vitamin D levels are common among dialysis patients, and observational studies have linked deficiency with worse outcomes. But an association does not show that supplementation prevents those outcomes. The trial’s overall result provides evidence against assuming that high-dose vitamin D3 improves survival for dialysis patients as a group. It does not, by itself, settle whether an individual with a measured deficiency should receive replacement under clinical guidance.
The findings may inform clinical discussions and future research, but they do not establish that vitamin D should never be used in this population. The trial tested a specific high-dose schedule against standard care; it was not a test of every dose, treatment strategy or patient subgroup.
Products Worth Considering
Bowflex PR1000 Home Gym
Therabody Theragun Relief Massage Gun, 3-Speed, Black
Oura Ring 4 Smart Ring – Silver – Size 8
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested Vitamin D3
Guidelines from Kidney Disease: Improving Global Outcomes suggest measuring 25-hydroxyvitamin D levels in people with stage 3-5 chronic kidney disease, including those on dialysis, and replacing vitamin D when levels are deficient. Smith said the guidelines acknowledge that the supporting evidence is of low certainty. SIMPLIFIED was designed to address that evidence gap by testing supplementation in a large dialysis population.
Participants had a median age of 65 years; 68% were men, 80% were white and 40% had diabetes. Nearly all, 94%, received in-center hemodialysis, and the median time on dialysis was 2.25 years. The study used a pragmatic approach: after an initial in-person assessment, follow-up visits were remote and outcome information came from routinely collected electronic health records.
Subgroup Signals Need Testing
Prespecified subgroup analyses suggested a possible benefit among men and participants of non-white ethnicity. Smith emphasized that the study was not powered to confirm effects in these groups, so the findings are exploratory rather than definitive. She said people of non-white ethnicity tend to have lower baseline vitamin D levels and that the signal could be worth examining in future studies.
Researchers also reported a nominal reduction in overall major adverse cardiovascular events, with a hazard ratio of 0.88 (95% CI 0.78-0.99; P=0.03). The difference was mainly associated with fewer peripheral arterial disease events (HR 0.80; 95% CI 0.65-0.99; P=0.04). Smith cautioned that the trial was not powered to confirm associations for these individual endpoints. The result does not establish a cardiovascular benefit, particularly alongside the lack of significant differences across the reported secondary outcomes.
The report does not establish whether a different dose, duration, or approach targeted specifically at people with documented deficiency would change outcomes. It also does not provide a basis for replacing individualized clinical care with the trial’s study schedule.
Further Trials May Examine Subgroups
The study results were presented at the American Society of Nephrology’s Kidney Week meeting. Future research could test whether the exploratory findings in men or non-white patients are reproducible, and whether targeted supplementation for patients with measured deficiency affects clinical outcomes. Any such findings would need confirmation in studies designed and powered to answer those questions.
For now, the available result is that the tested high-dose schedule did not significantly improve overall survival in the full trial population. Decisions about measuring or treating vitamin D deficiency remain a matter for clinicians and patients, guided by individual circumstances and applicable kidney-care guidance.
Key Questions
Did high-dose vitamin D improve survival in the trial?
No significant improvement was found. The reported conditional hazard ratio for overall survival was 0.95 (95% CI 0.86-1.04; P=0.26) over a median 7.5 years.
What vitamin D dose did researchers test?
Participants assigned to supplementation received 60,000 IU of cholecalciferol every two weeks. The comparison group received standard care without the study supplement.
Did the study find any possible benefits?
Exploratory analyses suggested possible benefit in men and non-white participants, and researchers reported a nominal reduction in major adverse cardiovascular events. The investigators said these findings were not definitive and require further study.
Does the result mean dialysis patients should not take vitamin D?
No. The trial tested one high-dose schedule and did not establish that all vitamin D treatment is ineffective or inappropriate. Kidney-care guidance suggests measuring vitamin D levels in people with advanced chronic kidney disease and replacing it when deficient; patients should discuss their care with a clinician.
Source: medpagetoday.com
